After years of cultivation, domestically produced innovative drugs have reached the initial stage of producing results, and ASCO's participation has further increased in '24
The research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was announced on April 25 and included about 5,900 abstracts.
Nearly 50 original domestically produced innovative drugs were selected for oral reports, more than doubling from 23; clinical studies of 5 original domestically produced innovative drugs were included in the latest breakthrough research (LBA).
Furthermore, ImmunityBio (IBRXUS) revealed that its IL-15 superagonist anktiva combined with PD-1 antibody significantly lengthens OS in patients with PD-1 antibody-resistant NSCLC, which is expected to overcome this huge market and become one of the key potential varieties in next-generation IO drugs; domestic companies are forwardly deploying IL-15, and the leader is in phase I/II clinical trials.
Huatai Securities believes that the global competitiveness of domestically produced innovative drugs has gradually been shown. They are in the first tier of the world in terms of clinical results and target/mechanism layout, and the innovative drug industry is expected to move towards a pillar industry in the future.
ICBC Credit Suisse Foundation believes that considering that the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in the second quarter will read out a large amount of ADC data, which will catalyze innovative drugs at that time, adding to the favorable policies of the industry itself, the innovative drug sector is still worth paying attention to in the long term.
Domestic innovative drug-related companies:
China Biopharmaceutical (01177): Announced the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor)”, “ibergrastin α (third-generation long-acting G-CSF)”, “piamprimab (anti-PD-1)”, and “FS222 (PD-L1/CD137 double antibody)”, “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728 (IAP antagonist)””, “TQB2930 (HER2 dual antibody)”, etc. will be in The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting announced 52 recent research results, covering clinical research and basic research on various tumors such as bone and soft tissue sarcoma, lung cancer, head and neck tumors, digestive system tumors, gynecological tumors, breast cancer, and malignant tumors.
Keji Pharmaceutical-B (02171): According to Keji Pharmaceutical-B's recent announcement, an abstract of the company's CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received as an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Zheshang Securities said that the company successfully commercialized CT053, is advancing CT041 Phase II domestically, and is looking forward to an NDA. The bank is optimistic that the company is a leading global solid tumor CAR-T company, and the successive commercialization of its CT053 and CT041 pipelines has brought growth.
Yasheng Pharmaceutical-B (06855.HK): Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449.
Hehuang Pharmaceutical (00013.HK): Data from the Phase III study on second-line treatment of gastric cancer with furoquintinib was announced at the American Society of Clinical Oncology General Conference Series.
Gacos-B (01167.HK): Announcement The company announced clinical data on patients with pancreatic cancer and other solid tumors treated by Golerese at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Annual Meeting (2024 ASCO GI) Oral Abstract Session (Oral Abstract Session).